glp-1 and osteoarthritis Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory anti-degradative actions in GLP-1 functions and GLP-1R signalling

Andrology, 11, 225-233

According to Couture Med Spa, citing a New England Journal of Medicine trial, tirzepatide users can lose up to 15% of their body weight over 18 months, a result the practice attributes to the peptide's dual action on GIP and GLP-1 receptors

However, gastrointestinal (GI) adverse events remain the most common limitations to long-term therapy

Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis Published online by Cambridge University Press: 30 November 2023 Abstract Recent reports of individuals experiencing suicidal and/or self-injurious behaviors while using liraglutide and semaglutide have heightened the concerns regarding neuropsychiatric safety of Glucagon-like peptide-1 agonists (GLP-1RAs)

These medications are game-changers for weight loss and blood sugar control, but they may inadvertently disrupt the body's ability to absorb key vitamins and minerals

She noted that the new findings align with what weve found in similar studies on the association of GLP-1 medications with lower risk of suicidal ideation. Its still important, though, for clinicians to assess mental health and suicidal thoughts among adolescents taking these medications, Volkow wrote in an e-mail, so that proper support can be given to those at risk and harmful health outcomes can be prevented. Adolescence can be a particularly difficult time for mental health, she added